An observational study in Chronic Plaque-type Psoriasis, sponsored by Istanbul Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Istanbul Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Neuralgia with a site in Turkey — 29 open to participants now, 30 under way, none of them phase 3. Neuralgia · Turkey.
Among the 79 studies in Neuralgia with a site in Turkey, this one is the 18th largest by planned enrollment of the 43 observational ones that give a count, is one of 19 that started in 2026, is one of 43 observational ones, reaches primary completion later than 16 of the 29 other live ones, and was the 77th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →29 of the 79 studies in Neuralgia with a site in Turkey are open now. Recruiting first, the newest first:
Marmara University · Sites in Turkey
Ages 18+
Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Sites in Turkey
Ages 18–65
Kutahya Health Sciences University · Sites in Turkey
Ages 18+
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · Sites in Turkey
Ages 18–65
Marmara University · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 102 across 232 observational studies indexed under Neuralgia.
Median enrollment 60 across the 36 interventional studies, 96 across the 43 observational. Of the 42 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 79 has an industry lead sponsor. The 10 most frequent:
Istanbul Training and Research Hospital is the lead sponsor of 66 studies on the registry; 15 are open to participants now.
Istanbul Training and Research Hospital has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuralgia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846410Istanbul Physical Medicine Rehabilitation Training and Research HospitalVirtual Reality-Based Hypnotherapy for Pain, Sleep, and Mood in Spinal Cord Injury | 2026-11 |
| NCT07844772Istanbul Training and Research HospitalSerum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis | 2026-12 |
| NCT06430918Bozyaka Training and Research HospitalNeuropathic Pain and it's Relation to Sleep Quality in Knee Osteoarthritis | 2026-12-01 |
| NCT07550348Ataturk UniversityBupivacaine-Lidocaine vs Bupivacaine for Ultrasound-Guided Popliteal Sciatic Nerve Block | 2026-12-01 |
| NCT07596823Ankara City Hospital BilkentHematological Indices and Sympathetic Block Response in Neuropathic Pain | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 79 studies in Neuralgia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to better understand whether blood levels of Substance P are related to pain, itching, altered pain sensations, central sensitization, psoriasis severity, and quality of life in adults with chronic plaque psoriasis.
The main questions this study aims to answer are:
Are serum Substance P levels associated with neuropathic pain features, central sensitization, psoriasis severity, pain, itching, and quality of life? Do serum Substance P levels and these clinical features differ among patients receiving different psoriasis treatments?
Researchers will compare three groups of patients: those receiving IL-17 inhibitor treatment, those receiving conventional systemic treatment with methotrexate or acitretin, and those receiving topical treatment only or no current treatment.
Participants will:
Have their psoriasis severity assessed and complete questionnaires about pain, itching, central sensitization, and quality of life.
Undergo a neurological examination. Participants who report pain will also be evaluated for neuropathic pain features using the DN4 questionnaire.
Provide a blood sample for measurement of serum Substance P and routine laboratory tests.
Undergo electromyography and nerve conduction studies if peripheral neuropathy is suspected during the neurological evaluation.
No treatment will be assigned or changed as part of this study.
Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by complex interactions between immune pathways, cutaneous inflammation, and the nervous system. In addition to visible skin lesions, patients may experience pruritus, pain, burning, tingling, and other sensory complaints that can substantially impair quality of life. Increasing evidence suggests that neuroimmune mechanisms may contribute to these symptoms. Substance P, a neuropeptide involved in neurogenic inflammation, nociception, and pruritus, may represent one of the mediators linking cutaneous inflammation with sensory symptoms in psoriasis. The IL-17 pathway may also interact with neuroimmune mechanisms involved in pain and pruritus.
This single-center, cross-sectional, observational study aims to investigate the relationship between serum Substance P levels and clinical features including neuropathic pain characteristics, central sensitization, psoriasis severity, pain intensity, pruritus intensity, and dermatology-related quality of life in adults with chronic plaque psoriasis. The study will also explore whether serum Substance P levels and clinical characteristics differ according to the patients current treatment approach.
Approximately 100 patients with chronic plaque psoriasis will be enrolled and evaluated in three treatment groups: patients receiving IL-17 inhibitor therapy, patients receiving conventional systemic therapy such as methotrexate or acitretin, and patients receiving topical therapy only or no current treatment. Treatment history and duration of current therapy will also be recorded.
Psoriasis severity will be assessed using the Psoriasis Area and Severity Index (PASI), and quality of life will be evaluated using the Dermatology Life Quality Index (DLQI). Pain and pruritus intensity will be recorded using Numeric Rating Scales (NRS), and central sensitization symptoms will be evaluated using the Central Sensitization Inventory (CSI).
The presence and localization of pain will be recorded, including whether the pain is associated with psoriatic plaques. In participants reporting pain, neuropathic pain characteristics will be assessed using the Douleur Neuropathique 4 Questions (DN4). DN4 scores will be recorded both as total scores and according to the validated cutoff, with scores of 4 or higher considered positive for neuropathic pain features. Participants without pain will not undergo DN4 assessment.
All participants will undergo a standardized neurological evaluation in collaboration with the Neurology Department. Neurological examination will include assessment for findings suggestive of peripheral neuropathy. Electromyography and nerve conduction studies will be performed when peripheral neuropathy is clinically suspected, and participants with confirmed peripheral neuropathy will be excluded from the relevant study analyses according to the study protocol.
Venous blood samples will be obtained for measurement of serum Substance P concentrations using an enzyme-linked immunosorbent assay (ELISA). Laboratory assessments will also include parameters used to identify potential causes of peripheral neuropathy or relevant systemic confounders, including glycated hemoglobin (HbA1c), fasting glucose, vitamin B12, renal and liver function tests, thyroid function tests, complete blood count, erythrocyte sedimentation rate, and C-reactive protein, as clinically appropriate.
The primary analyses will examine the associations between serum Substance P concentrations and clinical measures of neuropathic pain features, central sensitization, psoriasis severity, pain, pruritus, and quality of life. Comparisons across the three treatment groups will also be performed to explore whether neuroimmune and clinical profiles differ according to treatment exposure.
Adults with chronic plaque psoriasis who are followed at the Dermatology Department of Istanbul Training and Research Hospital and meet the study eligibility criteria will be included. Participants will be classified into three predefined groups according to their current psoriasis treatment: IL-17 inhibitor therapy, conventional systemic therapy with methotrexate or acitretin, and topical therapy only or treatment-naive. Participants will undergo clinical, patient-reported, laboratory, and neurological assessments during a single cross-sectional study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with chronic plaque psoriasis receiving an IL-17 inhibitor as part of routine clinical care. Participants are included according to their existing treatment, and no treatment is assigned or modified by the study.
Biological: IL-17 Inhibitor Therapy
Patients with chronic plaque psoriasis receiving conventional systemic treatment with methotrexate or acitretin as part of routine clinical care. No treatment is assigned or modified by the study.
Drug: Conventional Systemic Therapy
Patients with chronic plaque psoriasis receiving topical therapy only or who have not yet received any treatment for psoriasis. Participants in this group have not received systemic therapy, biologic therapy, or phototherapy within the previous 6 months.
Exposure to IL-17 inhibitor therapy prescribed as part of routine clinical care for chronic plaque psoriasis. Treatment is not assigned, initiated, or modified by the study. Participants are classified according to their current treatment at the time of study assessment.
Exposure to conventional systemic therapy with methotrexate or acitretin prescribed as part of routine clinical care for chronic plaque psoriasis. Treatment is not assigned, initiated, or modified by the study.
Association Between Serum Substance P Levels and DN4 Score
The association between serum Substance P concentration measured by ELISA and the total Douleur Neuropathique 4 Questions (DN4) score will be evaluated among participants who report pain and undergo DN4 assessment. DN4 scores range from 0 to 10, with scores ≥4 considered positive for neuropathic pain features.
Time frame: Baseline (Day 1)
Association Between Serum Substance P Levels and Central Sensitization Inventory Score
The association between serum Substance P concentration and the Central Sensitization Inventory (CSI) Part A total score will be evaluated. Part A consists of 25 items, with total scores ranging from 0 to 100. Higher scores indicate a greater burden of symptoms associated with central sensitization.
Time frame: Baseline (Day 1)
Association Between Serum Substance P Levels and Psoriasis Severity
The association between serum Substance P concentration and psoriasis severity measured by the Psoriasis Area and Severity Index (PASI) will be evaluated. PASI ranges from 0 to 72, with higher scores indicating greater disease severity.
Time frame: Baseline (Day 1)
Association Between Serum Substance P Levels and Pain Intensity
The association between serum Substance P concentration and pain intensity measured using a 0-10 Numeric Rating Scale (NRS) will be evaluated, with higher scores indicating greater pain intensity.
Time frame: Baseline (Day 1)
Association Between Serum Substance P Levels and Pruritus Intensity
The association between serum Substance P concentration and pruritus intensity measured using a 0-10 Numeric Rating Scale (NRS) will be evaluated, with higher scores indicating greater pruritus intensity.
Time frame: Baseline (Day 1)
Association Between Serum Substance P Levels and Dermatology-Related Quality of Life
The association between serum Substance P concentration and the Dermatology Life Quality Index (DLQI) score will be evaluated. DLQI ranges from 0 to 30, with higher scores indicating greater impairment in quality of life.
Time frame: Baseline (Day 1)
Differences in Serum Substance P Levels Across Treatment Groups
Serum Substance P concentrations will be compared among participants receiving IL-17 inhibitor therapy, conventional systemic therapy with methotrexate or acitretin, and topical therapy only or no previous/current systemic treatment according to the study group definitions.
Time frame: Baseline (Day 1)
Psoriasis Area and Severity Index (PASI) Score Across Treatment Groups
The Psoriasis Area and Severity Index (PASI) total score will be compared across the three predefined treatment groups. Scores range from 0 to 72, with higher scores indicating greater psoriasis severity.
Time frame: Baseline (Day 1)
Central Sensitization Inventory (CSI) Score Across Treatment Groups
The Central Sensitization Inventory (CSI) Part A total score will be compared across the three predefined treatment groups. Part A consists of 25 items, with total scores ranging from 0 to 100. Higher scores indicate a greater burden of symptoms associated with central sensitization.
Time frame: Baseline (Day 1)
Dermatology Life Quality Index (DLQI) Score Across Treatment Groups
The Dermatology Life Quality Index (DLQI) total score will be compared across the three predefined treatment groups. Total scores range from 0 to 30, with higher scores indicating greater impairment of dermatology-related quality of life.
Time frame: Baseline (Day 1)
Pain Numeric Rating Scale (NRS) Score Across Treatment Groups
Pain intensity assessed using the Numeric Rating Scale (NRS) will be compared across the three predefined treatment groups. Scores range from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.
Time frame: Baseline (Day 1)
Pruritus Numeric Rating Scale (NRS) Score Across Treatment Groups
Pruritus intensity assessed using the Numeric Rating Scale (NRS) will be compared across the three predefined treatment groups. Scores range from 0 (no itch) to 10 (worst imaginable itch), with higher scores indicating greater pruritus intensity.
Time frame: Baseline (Day 1)
Douleur Neuropathique 4 Questions (DN4) Score Across Treatment Groups
The Douleur Neuropathique 4 Questions (DN4) total score will be compared across the three predefined treatment groups among participants who report pain and undergo DN4 assessment. Total scores range from 0 to 10, with higher scores indicating a greater number of neuropathic pain features. A score of 4 or higher indicates a positive screening result for neuropathic pain.
Time frame: Baseline (Day 1)
Neurological Sensory Symptoms and Sensory Examination Findings
The presence of sensory symptoms including burning, stinging, electric shock-like sensations, tingling, numbness, pins and needles, pain associated with itching, pain evoked by touch, and sensitivity to heat or cold will be recorded. Sensory examination findings including vibration sensation, pinprick sensation, allodynia, and hyperalgesia will also be documented during the neurological examination. The frequency and distribution of these symptoms and examination findings will be evaluated.
Time frame: Baseline (Day 1)
Plan to share: No — Individual participant data will not be shared because there is currently no predefined plan or ethical approval for sharing de-identified participant-level data with researchers outside the study team. Study findings will be reported in aggregate form in scientific outputs.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Training and Research Hospital